Vistagen Therapeutics sued for securities violations, deadline March 16, 2026.

Vistagen Therapeutics, Inc. faces a class-action lawsuit for allegedly violating the Securities Exchange Act of 1934. The lawsuit claims that the company made false and misleading statements regarding the results of its PALISADE-2 trial of fasedienol, creating a false impression that the drug candidate would succeed in Phase 3 trials. Shareholders who purchased VTGN shares during the class period (April 1, 2024 to December 16, 2025) are encouraged to contact the firm regarding possible lead plaintiff appointments. The deadline to participate is March 16, 2026.